Gabapentin capsules recalled after stability testing found unknown impurity out of specification
The Harvard Drug Group is recalling Gabapentin Capsules USP 100 mg across several lots after routine stability testing returned an out-of-specification result for highest unknown impurity.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: Scored 2 as a specification failure: the record cites an out-of-specification unknown impurity without naming it, describing a health consequence, or reporting injury.
Plain-English summary
Gabapentin Capsules, USP, 100 mg, in 100-capsule blister packs, packaged and distributed by Major Pharmaceuticals of Indianapolis, Indiana, are being recalled for failed impurities and degradation specifications.
An out-of-specification result was obtained during routine stability testing for highest unknown impurity.
The recall covers lots including M04950 (expiring January 2026), M04989 and M04990 (expiring February 2026) and M05056 (expiring April 2026), carrying NDC 0904-6665-61. The product was distributed nationwide in the United States. The FDA has classified the recall as Class II.
The enforcement record states the specification failure without naming the impurity or describing a health consequence, and reports no injuries. Gabapentin is a prescription medicine, so patients holding an affected lot should contact their pharmacy or prescriber about a replacement rather than stopping treatment on their own.
The recalled product
- Product
- GABAPENTIN (GABAPENTIN)
- Brand
- GABAPENTIN
- Manufacturer
- The Harvard Drug Group LLC
- Category
- Drug — Anticonvulsant
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (17)
- Lot # M04950
- Exp Date: 01/2026
- Lot # M04989
- M04990
- Exp Date: 02/2026
- Lot # M05056
- Exp Date: 04/2026
- Lot # M05150
- Exp Date: 07/2026
- Lot # M05290
- Exp Date: 11/2026
- Lot # M05312
- M05342
- Exp Date: 01/2027
- Lot # M05369
- M05386
- Exp Date: 02/2027.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by The Harvard Drug Group LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · GABAPENTIN
- ModerateGabapentin blister packs recalled after unknown impurity exceeded specification
FDA (Drugs) · 2025-10-29
- ModerateGabapentin Capsules 100 mg recalled for defective blister packaging
FDA (Drugs) · 2025-07-09
- ModerateGabapentin capsule bags recalled because blister packaging was inadequately sealed
FDA (Drugs) · 2025-07-09
- LowGabapentin Capsules Recalled for Cross Contamination
FDA (Drugs) · 2025-04-16
- LowGabapentin Capsules 400 mg Recalled for Cross Contamination
FDA (Drugs) · 2025-04-16
Same manufacturer · The Harvard Drug Group LLC
See all →- ModerateMETHYLERGONOVINE MALEATE Tablets 0.2 mg Drug Recall
FDA (Drugs) · 2026-07-01
- ModerateOmega-3-Acid Ethyl Esters capsules recalled for failed capsule specifications
FDA (Drugs) · 2026-04-29
- HighMajor Pharmaceuticals memantine extended-release capsules fail dissolution specifications
FDA (Drugs) · 2026-04-22
- ModerateMidodrine hydrochloride tablets recalled over inadequately sealed blister packaging
FDA (Drugs) · 2026-03-11
Same hazard · impurity
See all →- ModerateAjanta Pharma Recalls Fluphenazine Hydrochloride Tablets Due to Impurity Failure
FDA (Drugs) · 2026-09-16
- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
Similar recalls
- ModerateGabapentin Capsules 100 mg recalled for defective blister packaging
FDA (Drugs) · 2025-07-09
- LowInvaGen Recalls Gabapentin Tablets Due to Impurity Test Failure
FDA (Drugs) · 2020-05-27
- HighPrescription Rifampin Capsules Recalled for Failed Impurity Specifications
FDA (Drugs) · 2023-01-18
- ModerateGabapentin capsule bags recalled because blister packaging was inadequately sealed
FDA (Drugs) · 2025-07-09
- ModerateAkorn Recalls Gabapentin Oral Solution Due to Impurity Specifications
FDA (Drugs) · 2021-03-24
- SevereAlprazolam Tablets Recalled for Unknown Impurity
FDA (Drugs) · 2017-10-25